ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (19)
  • American Chemical Society (ACS)  (4)
  • Oxford University Press  (3)
  • American Association for the Advancement of Science (AAAS)  (2)
  • Nature Publishing Group (NPG)
  • 2010-2014  (29)
  • 1940-1944
  • 2011  (29)
Collection
Publisher
Years
  • 2010-2014  (29)
  • 1940-1944
Year
  • 1
    Publication Date: 2011-03-11
    Description: Analytical Chemistry DOI: 10.1021/ac102829b
    Print ISSN: 0003-2700
    Electronic ISSN: 1520-6882
    Topics: Chemistry and Pharmacology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    Publication Date: 2011-07-27
    Description: Langmuir DOI: 10.1021/la1051063
    Print ISSN: 0743-7463
    Electronic ISSN: 1520-5827
    Topics: Chemistry and Pharmacology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 3
    Publication Date: 2011-08-24
    Description: Chemical Reviews DOI: 10.1021/cr200084z
    Print ISSN: 0009-2665
    Electronic ISSN: 1520-6890
    Topics: Chemistry and Pharmacology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 4
    Publication Date: 2011-08-24
    Description: Analytical Chemistry DOI: 10.1021/ac2015239
    Print ISSN: 0003-2700
    Electronic ISSN: 1520-6882
    Topics: Chemistry and Pharmacology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 5
    Publication Date: 2011-03-26
    Description: Pervasive transcription of eukaryotic genomes generates a plethora of noncoding RNAs. In fission yeast, the heterochromatin factor Clr4/Suv39 methyltransferase facilitates RNA interference (RNAi)-mediated processing of centromeric transcripts into small interfering RNAs (siRNAs). Clr4 also mediates degradation of antisense RNAs at euchromatic loci, but the underlying mechanism has remained elusive. We show that Clr4 and the RNAi effector RITS (RNA-induced transcriptional silencing) interact with Mlo3, a protein related to mRNA quality control and export factors. Loss of Clr4 impairs RITS interaction with Mlo3, which is required for centromeric siRNA production and antisense suppression. Mlo3 also interacts with the RNA surveillance factor TRAMP, which suppresses antisense RNAs targeted by Clr4 and RNAi. These findings link Clr4 to RNA quality control machinery and suggest a pathway for processing potentially deleterious RNAs through the coordinated actions of RNAi and other RNA processing activities.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Zhang, Ke -- Fischer, Tamas -- Porter, Rebecca L -- Dhakshnamoorthy, Jothy -- Zofall, Martin -- Zhou, Ming -- Veenstra, Timothy -- Grewal, Shiv I S -- Intramural NIH HHS/ -- New York, N.Y. -- Science. 2011 Mar 25;331(6024):1624-7. doi: 10.1126/science.1198712.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Laboratory of Biochemistry and Molecular Biology, National Cancer Institute/NIH, Bethesda, MD 20892, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21436456" target="_blank"〉PubMed〈/a〉
    Keywords: Cell Cycle Proteins/genetics/*metabolism ; Centromere/metabolism ; Euchromatin/metabolism ; Histones/metabolism ; Methylation ; Methyltransferases/genetics/*metabolism ; Mutation ; *RNA Interference ; RNA Processing, Post-Transcriptional ; RNA, Antisense/*metabolism ; RNA, Fungal/*metabolism ; RNA-Binding Proteins/metabolism ; Saccharomyces cerevisiae Proteins/metabolism ; Schizosaccharomyces/*genetics/*metabolism ; Schizosaccharomyces pombe Proteins/genetics/*metabolism
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 6
    Publication Date: 2011-01-08
    Description: A young and energetic pulsar powers the well-known Crab Nebula. Here, we describe two separate gamma-ray (photon energy greater than 100 mega-electron volts) flares from this source detected by the Large Area Telescope on board the Fermi Gamma-ray Space Telescope. The first flare occurred in February 2009 and lasted approximately 16 days. The second flare was detected in September 2010 and lasted approximately 4 days. During these outbursts, the gamma-ray flux from the nebula increased by factors of four and six, respectively. The brevity of the flares implies that the gamma rays were emitted via synchrotron radiation from peta-electron-volt (10(15) electron volts) electrons in a region smaller than 1.4 x 10(-2) parsecs. These are the highest-energy particles that can be associated with a discrete astronomical source, and they pose challenges to particle acceleration theory.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Abdo, A A -- Ackermann, M -- Ajello, M -- Allafort, A -- Baldini, L -- Ballet, J -- Barbiellini, G -- Bastieri, D -- Bechtol, K -- Bellazzini, R -- Berenji, B -- Blandford, R D -- Bloom, E D -- Bonamente, E -- Borgland, A W -- Bouvier, A -- Brandt, T J -- Bregeon, J -- Brez, A -- Brigida, M -- Bruel, P -- Buehler, R -- Buson, S -- Caliandro, G A -- Cameron, R A -- Cannon, A -- Caraveo, P A -- Casandjian, J M -- Celik, O -- Charles, E -- Chekhtman, A -- Cheung, C C -- Chiang, J -- Ciprini, S -- Claus, R -- Cohen-Tanugi, J -- Costamante, L -- Cutini, S -- D'Ammando, F -- Dermer, C D -- de Angelis, A -- de Luca, A -- de Palma, F -- Digel, S W -- do Couto e Silva, E -- Drell, P S -- Drlica-Wagner, A -- Dubois, R -- Dumora, D -- Favuzzi, C -- Fegan, S J -- Ferrara, E C -- Focke, W B -- Fortin, P -- Frailis, M -- Fukazawa, Y -- Funk, S -- Fusco, P -- Gargano, F -- Gasparrini, D -- Gehrels, N -- Germani, S -- Giglietto, N -- Giordano, F -- Giroletti, M -- Glanzman, T -- Godfrey, G -- Grenier, I A -- Grondin, M-H -- Grove, J E -- Guiriec, S -- Hadasch, D -- Hanabata, Y -- Harding, A K -- Hayashi, K -- Hayashida, M -- Hays, E -- Horan, D -- Itoh, R -- Johannesson, G -- Johnson, A S -- Johnson, T J -- Khangulyan, D -- Kamae, T -- Katagiri, H -- Kataoka, J -- Kerr, M -- Knodlseder, J -- Kuss, M -- Lande, J -- Latronico, L -- Lee, S-H -- Lemoine-Goumard, M -- Longo, F -- Loparco, F -- Lubrano, P -- Madejski, G M -- Makeev, A -- Marelli, M -- Mazziotta, M N -- McEnery, J E -- Michelson, P F -- Mitthumsiri, W -- Mizuno, T -- Moiseev, A A -- Monte, C -- Monzani, M E -- Morselli, A -- Moskalenko, I V -- Murgia, S -- Nakamori, T -- Naumann-Godo, M -- Nolan, P L -- Norris, J P -- Nuss, E -- Ohsugi, T -- Okumura, A -- Omodei, N -- Ormes, J F -- Ozaki, M -- Paneque, D -- Parent, D -- Pelassa, V -- Pepe, M -- Pesce-Rollins, M -- Pierbattista, M -- Piron, F -- Porter, T A -- Raino, S -- Rando, R -- Ray, P S -- Razzano, M -- Reimer, A -- Reimer, O -- Reposeur, T -- Ritz, S -- Romani, R W -- Sadrozinski, H F-W -- Sanchez, D -- Saz Parkinson, P M -- Scargle, J D -- Schalk, T L -- Sgro, C -- Siskind, E J -- Smith, P D -- Spandre, G -- Spinelli, P -- Strickman, M S -- Suson, D J -- Takahashi, H -- Takahashi, T -- Tanaka, T -- Thayer, J B -- Thompson, D J -- Tibaldo, L -- Torres, D F -- Tosti, G -- Tramacere, A -- Troja, E -- Uchiyama, Y -- Vandenbroucke, J -- Vasileiou, V -- Vianello, G -- Vitale, V -- Wang, P -- Wood, K S -- Yang, Z -- Ziegler, M -- New York, N.Y. -- Science. 2011 Feb 11;331(6018):739-42. doi: 10.1126/science.1199705. Epub 2011 Jan 6.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉National Research Council Research Associate, National Academy of Sciences, Washington, DC 20001, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21212321" target="_blank"〉PubMed〈/a〉
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 7
    Publication Date: 2011-01-07
    Description: 〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Porter, John R -- Deutsch, Lisa -- Dumaresq, David -- Dyball, Rob -- England -- Nature. 2011 Jan 6;469(7328):34. doi: 10.1038/469034d.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21209650" target="_blank"〉PubMed〈/a〉
    Keywords: Agriculture/statistics & numerical data/*trends ; Cities/*statistics & numerical data ; Food Supply/*statistics & numerical data ; *Population Growth ; Urban Population/*statistics & numerical data/trends
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 8
    Publication Date: 2011-11-18
    Description: Abstract 1869 BACKGROUND: The aggresome/autophagy pathway is the primary mechanism for disposal of ubiquitinated proteins for cells exposed to proteasome inhibition. Preclinical evidence shows that combining inhibition of the proteasome with bortezomib (Bz) and inhibition of autophagy with the anti-malarial drug hydroxychloroquine (HCQ) leads to enhanced cytotoxicity in myeloma cells. METHODS: Patients with relapsed or refractory myeloma enrolled on a standard 3+3 dose escalation design. Patients received 2-weeks of single-agent oral HCQ, followed by the addition of Bz on days 1, 4, 8, and 11 of 21-day cycles. HCQ and Bz doses were determined by dose level: (1) 200 mg qod / 1.0 mg/m2, (2) 200 qod / 1.3, (3) 200 qd / 1.3, (4) 200 bid / 1.3, (5) 400 bid / 1.3, (6) 600 bid / 1.3. Dose-limiting toxicity (DLT) was defined as grade ≥3 toxicity probably related to study therapy and occurring during the first 5 weeks, with the exception of any anemia or lymphopenia, neutropenia responsive to growth factor, platelets 〉10,000/mm3 not associated with bleeding, or gastrointestinal complaints relieved by symptomatic therapy. We used electron microscopy to characterize changes in autophagic vesicles in serial samples of peripheral blood mononuclear cells and CD138-selected bone marrow plasma cells. RESULTS: We enrolled 25 patients between 1/2008 and 2/2011, of which 21 patients completed at least 1 cycle of combined therapy and were evaluable for toxicity. The median duration of study participation was 14 weeks (range 1–77). Reasons for study discontinuation were side effects of therapy (6), lack of response (7), disease progression (11), and non-compliance (1). No protocol-defined dose limiting toxicities occurred, and the maximum tolerated dose was determined to be the top dose level of Bz 1.3 mg/m2 and HCQ 600 mg twice daily. Hematologic abnormalities were generally more attributable to disease progression than to treatment toxicity, but at the top dose level one patient had grade 3 thrombocytopenia and neutropenia after starting with a normal platelet count and ANC, without evidence of progression through therapy. At the top dose level, gastrointestinal toxicities predominated, including 5 out of 6 evaluable patients with some form of grade 3 GI toxicity. Treatment emergent neuropathy occurred in 7 patients but was restricted to grade 1 or 2 and was easily managed with dose reduction of the Velcade. Three patients came off study before receiving the combined regimen and were not evaluable for response. The best responses for the remaining 22 patients included 3 near complete responses (nCR), 3 minor responses (MR), 9 stable disease (SD), and 7 progression (PD). The 3 nCRs occurred in Bz-naïve patients receiving HCQ at 400 mg/d (1 pt) and 1200 mg/d (2 pts). Two patients who had previously progressed while receiving weekly maintenance Bz had MRs on study, including one who maintained a MR for over 7 months. Three additional Bz-refractory patients initially achieved stable disease during study treatment, with on study TTP of 8 weeks (at HCQ 1200 mg/d), 15 weeks (100 mg/d), and 17 weeks (200 mg/d). Preliminary analyses of vesicle counts at HCQ doses up to 800 mg/d identify individual patients with increases in autophagic vesicles in either peripheral blood or bone marrow plasma cells, but these are not consistent, nor is there any evident correlation with response. CONCLUSION: Combined Bz and HCQ is tolerable, with a phase 2 dose of Bz 1.3 mg/m2 and HCQ 1200 mg/d and likely hematologic and gastrointestinal DLTs. There is a suggestion of improved efficacy over Bz alone, with minor responses and long periods of stable disease in Bz-refractory patients. Final analysis of autophagy inhibition in correlative specimens, including the top dose cohort, will be available for the meeting. Disclosures: Vogl: Millennium Pharmaceuticals: Honoraria, Research Funding. Off Label Use: Hydroxychloroquine is FDA approved for treatment of malaria and rheumatoid arthritis. This paper discusses its use in treatment of myeloma. Carroll:Agios Pharmaceuticals: Research Funding; TetraLogic Pharmaceuticals: Research Funding; Sanofi Aventis Corporation: Research Funding; Glaxo Smith Kline, Inc.: Research Funding. Amaravadi:Millennium Pharmaceuticals: Honoraria, Research Funding.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 9
    Publication Date: 2011-07-28
    Description: Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year, phase 3, randomized trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ≥ 1 deferasirox dose, 66.8% completed the study; 43 patients (7.7%) discontinued because of adverse events. In patients with ≥ 4 years' deferasirox exposure who had liver biopsy, mean liver iron concentration significantly decreased by 7.8 ± 11.2 mg Fe/g dry weight (dw; n = 103; P 〈 .001) and 3.1 ± 7.9 mg Fe/g dw (n = 68; P 〈 .001) in the deferasirox and crossover cohorts, respectively. Median serum ferritin significantly decreased by 706 ng/mL (n = 196; P 〈 .001) and 371 ng/mL (n = 147; P 〈 .001), respectively, after ≥ 4 years' exposure. Investigator-assessed, drug-related adverse events, including increased blood creatinine (11.2%), abdominal pain (9.0%), and nausea (7.4%), were generally mild to moderate, transient, and reduced in frequency over time. No adverse effect was observed on pediatric growth or adolescent sexual development. This first prospective study of long-term deferasirox use in pediatric and adult patients with β-thalassemia suggests treatment for ≤ 5 years is generally well tolerated and effectively reduces iron burden. This trial was registered at www.clinicaltrials.gov as #NCT00171210.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 10
    Publication Date: 2011-11-18
    Description: Abstract 1344 Background: Although reports are emerging of hematologic responses associated with iron chelation therapy in patients with myelodysplastic syndromes (MDS, eg, Gattermann et al. Blood 2010;116(21):abst 2912), there are limited studies in aplastic anemia (AA) patients. The EPIC study enrolled 116 transfusion-dependent AA patients with iron overload (Cappellini et al. Haematologica 2010; Lee et al. Blood 2010); deferasirox treatment resulted in a decrease in iron overload assessed by serum ferritin. As iron overload has a suppressive effect on erythroid progenitors (Hartmann et al. Blood 2008;112(11):abst 2694), it is of interest to evaluate hematologic responses with the iron chelator deferasirox in AA patients from the EPIC trial. Methods: Full study design and inclusion/exclusion criteria for EPIC have been described (Cappellini et al. Haematologica 2010). Deferasirox dose was initiated at 20 mg/kg/day with adjustments of 5–10 mg/kg/day up to 40 mg/kg/day based on serum ferritin trends and safety assessments. For this post-hoc analysis of hematologic response and the classification of patients, UK treatment guideline criteria for AA diagnosis (2 or 3 of the following: hemoglobin [Hb] 3 g/dL if initially 0.5 × 109/L if initially 20 × 109/L if initially
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...